科達利(002850.SZ)披露A股定增報告書:易方達、銀華基金及南方基金等參投
格隆匯11月29日丨科達利(002850.SZ)披露非公開發行A股股票發行情況報告書暨上市公告書,根據投資者申購報價情況,並嚴格按照《認購邀請書》中確定的發行價格、發行對象及獲配股份數量的程序和規則,確定本次發行價格為60.47元/股,發行股數為2292.0451萬股,募集資金總額約13.86億元。
此次發行對象最終確定為14家,均在169名發送《認購邀請書》特定對象名單內,此次發行配售結果如下:

股票上市時間為2020年12月1日,新增股份上市首日不除權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.